Equillium Inc
USUSDEquillium Inc (US:EQ) — Biotechnology: Pharmaceutical Preparations. Número de bolsas en las que cotizan las acciones de la empresa: 2. En esta página: cotización y gráfico, dividendos, principales accionistas e historial del número de acciones.
Sobre la empresa
- Sitio web
- equilliumbio.com
- Sector
- Health Care · Biotechnology: Pharmaceutical Preparations
- Sede central
- LA JOLLA, United States
- Consejero delegado
- Bruce Steel
- Empleados
- 14
- Acciones en circulación
- 63.41 M a 2026-08-07
- Capital flotante
- 36.97 M
- Capitalización bursátil
- 89.41 M USD
- Insiders
- 16%
- Inversores institucionales
- 65.76%
- Industria (SIC)
- Pharmaceutical Preparations
- FCF
- −20.1 M USD
- Deuda
- 7.64 M USDcaja neta
- Resultados y FCF — para los 12 meses hasta 30.06.2026 (el último informe de la empresa).
Descripción
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Noticias de esta semana
Comunicados de prensa desde la página web para inversores de la empresa, actualizados diariamente. Los enlaces conducen a la página web de la empresa. Los titulares están en el idioma original, como en la página web de la empresa.
Principales accionistas
| Titular | Participación | Acciones | Fecha del informe |
|---|---|---|---|
| Jupiter Topco LLC | 10.24% | 6.49 M | 2026-06-30 |
| Decheng Capital LLC | 7.01% | 4.45 M | 2026-06-30 |
| Affinity Asset Advisors,… | 6.47% | 4.1 M | 2026-06-30 |
| Adar1 Capital Management… | 5.93% | 3.76 M | 2026-06-30 |
| Aberdeen Group plc | 5.73% | 3.63 M | 2026-06-30 |
| abrdn Life Sciences Inve… | 5.73% | 3.63 M | 2026-06-30 |
| Woodline Partners LP | 5.52% | 3.5 M | 2026-06-30 |
| RA Capital Management, L… | 4.88% | 3.1 M | 2026-06-30 |
| Stempoint Capital LP | 3.18% | 2.02 M | 2026-06-30 |
| Vanguard Capital Managem… | 2.87% | 1.82 M | 2026-06-30 |
| Eversept Partners, LP | 2.4% | 1.52 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.21% | 1.4 M | 2026-06-30 |
| CONNELLY STEPHEN (Presid… | ≈1.2% | 762 025 | 2026-06-05 |
| VANGUARD INDEX FUNDS-Van… | 0.54% | 344 489 | 2026-06-30 |
| Fidelity Concord Street… | 0.26% | 162 851 | 2026-07-31 |
| iShares Trust-iShares Mi… | 0.24% | 153 076 | 2026-08-31 |
| American Century ETF Tru… | 0.12% | 75 411 | 2026-08-31 |
| ZEDELMAYER CHRISTINE (Ch… | ≈0.1% | 62 586 | 2026-06-05 |
| Fidelity Concord Street… | 0.09% | 54 677 | 2026-07-31 |
| Fidelity Concord Street… | 0.07% | 47 465 | 2026-07-31 |
| Invesco Exch-Trd Fd. TRT… | 0.06% | 38 516 | 2026-08-31 |
| Fidelity Concord Street… | 0.06% | 36 683 | 2026-07-31 |
| TOM PENNY (Officer) | — | 0 | 2026-05-28 |
| KEYES JASON A (Chief Fin… | — | — | 2025-01-23 |
